Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Treatment of atopic dermatitis with dupilumab: experience from a tertiary referral centre

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Identification of pigments related to allergic tattoo reactions in 104 human skin biopsies

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. A job-exposure matrix addressing hand exposure to wet work

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. The inhabitants of our skin

    Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

Vis graf over relationer

BACKGROUND: Management of moderate-to-severe atopic dermatitis (AD) frequently requires treatment with systemic therapies. Dupilumab is the first biological agent approved for treatment of moderate-to-severe AD. Although promising results have appeared in clinical trials, real-life data on efficacy and safety are lacking.

OBJECTIVES: To assess effectiveness and safety of treatment with dupilumab in the real-life clinical setting at a Danish tertiary referral centre.

METHODS: All patients with AD treated with dupilumab from October 2017 to October 2018 at Bispebjerg Hospital, Denmark, were included in the study. Patients were evaluated three times: at treatment initiation and at 1 and 3 months after first dupilumab injection. At each visit, disease activity was assessed by severity score (Eczema Area and Severity Index, EASI), patient-reported outcomes (Dermatology Life Quality Index, DLQI, pruritus and sleep score) and serological markers [immunoglobulin (Ig)E, eosinophil count and lactate dehydrogenase (LDH)].

RESULTS: A total of 43 patients were included in the study. The mean reduction in EASI score from baseline was 19.6 points (72.4%) at 1-month and 22.6 points (76.7%) at 3-month follow-up. EASI, DLQI, pruritus score, sleep score, IgE and LDH were all statistically significantly reduced between baseline and 1- and 3-month follow-up. Mean reductions in EASI score and LDH at 3-month follow-up were significantly correlated (P = 0.003). One patient (2.3%) discontinued treatment due to side-effects, and seven patients (18.4%) developed conjunctivitis during the study period.

CONCLUSION: The effectiveness and safety of dupilumab treatment in a real-life clinical setting are comparable to that of phase 3 clinical trials. LDH is suggested as a potential serological marker predictive of treatment response.

OriginalsprogEngelsk
TidsskriftJournal of the European Academy of Dermatology and Venereology : JEADV
Vol/bind33
Udgave nummer8
Sider (fra-til)1562-1568
Antal sider7
ISSN0926-9959
DOI
StatusUdgivet - aug. 2019

Bibliografisk note

© 2019 European Academy of Dermatology and Venereology.

ID: 58953852